TFS acquires Beardsworth Consulting Group, a CRO specializing in oncology and vaccines
Trial Form Support is the most important private Contract Research Organization (CRO) in Europe and twelfth in the world. They have had a subsidiary in Barcelona since 2005.
By Biocat
Trial Form Support (TFS), a CRO specializing in the development of clinical drugs which has a subsidiary in Barcelona, has acquired the CRO Beardsworth Consulting Group (BCG), created in 1986 in New Jersey and specializing in clinical trials in oncology and vaccines. With this acquisition TFS aims to expand its research services in these fields and grow operations in the United States to have 600 professionals there. TFS currently has 500 people on staff in the 19 countries where it operates —17 in Europe, the United States and Japan.
CEO of TFS Daniel Spasic explains that the agreement is highly significant as it "adds competencies in active and growing therapeutic areas, increases our operational capabilities in North America and substantially expands our customer portfolio of smaller and midsized life sciences companies in the most important global research markets.”
BCG carried out operations associated with clinical research, project and data management, monitoring all phases of trials, biostatistics and regulatory and legal consulting. Although the terms and conditions have not been revealed, the process of integrating the two CROs will be facilitated by the fact that they have previously collaborated on various clinical programs in oncology and other therapeutic areas.
In the past five months, TFS has carried out two similar acquisitions: Italian company Dimensione Ricerca and Swedish technology supplier for electronic data-capture services Semcon.
Since September 2011, Dr. Montserrat Barceló of Catalonia has served as executive vice-president for Europe at TFS after joining the company in July 2005.
Related news (28/9/2011)